Anti-Aging Drug Discovery Targeting S6K

S6 kinase (S6K) is a serine/threonine kinase that is primarily regulated by the mTOR (mechanistic target of rapamycin) signaling pathway. This pathway is integral to cellular growth, proliferation, and survival, linking nutrient availability to cellular function. As organisms age, dysregulation of mTOR signaling and S6K activity has been observed, contributing to age-related decline in cellular function and increased susceptibility to diseases. Furthermore, S6K has been implicated in the regulation of autophagy, a critical process for cellular maintenance that declines with age.

Fig. 1 S6K activity in the fat body of adult flies determines longevity. (Zhang P, et al., 2024)

CD BioSciences employs a multifaceted approach to help clients identify and develop anti-aging drugs that target the S6K signaling pathway. Our discovery process integrates advanced technologies and a deep understanding of the molecular mechanisms of aging.

How Do We Discover Anti-Aging Drugs Targeting S6K?

Drug screening and optimization

We help clients design and synthesize compounds that directly inhibit S6K activity and reduce its overactivation associated with aging. With automation tools, we help clients perform high-throughput screening (HTS) on large compound libraries to identify drug candidates that can inhibit S6K activity. We develop and validate robust cell-based assays that accurately measure S6K activity. CD BioSciences also specializes in optimizing drug candidates to enhance their anti-aging potential.

Preclinical testing

We provide a range of in vitro assays to assess the activity of drug candidates inhibiting the S6K pathway and their potential effects on downstream aging-related signaling pathways. We also help clients conduct in vivo studies to evaluate the pharmacodynamic and pharmacokinetic properties of drug candidates. We offer critical data on drug efficacy, dosing, and toxicity.

Evaluation of the Effects of Anti-Aging Drugs Targeting S6K

Evaluation of the role of anti-aging drugs targeting S6K in lowering inflammaging

We use human or animal cell lines to assess the impact of S6K inhibitors on inflammatory markers. Additionally, we help clients measure key inflammatory cytokine and protein levels before and after treatment with anti-aging drugs targeting S6K. We also analyze changes in signaling pathways associated with inflammaging, such as NF-κB and JAK/STAT, following S6K inhibition, providing insights into the mechanisms of action and potential therapeutic benefits of drug candidates.

Evaluation of the role of anti-aging drugs targeting S6K in extending lifespan

We help clients customize aging animal models to evaluate the drug efficacy of S6K inhibitors on lifespan. Our experts establish control and treatment groups with varying doses of the drug, assisting clients in assessing lifespan and physiological functions.

CD BioSciences is dedicated to exploring the S6K signaling pathway as a therapeutic target for helping clients develop anti-aging drugs. Our comprehensive approach to drug discovery, supported by robust screening and optimization processes, allows clients to develop novel therapeutics that combat inflammaging and promote healthy aging. If you are interested in our services, please feel free to contact us or make an online inquiry.

Reference

1. Zhang P, et al. Inhibition of S6K lowers age-related inflammation and increases lifespan through the endolysosomal system. Nat Aging, 2024, 4 (4): 491-509.